Form 4: MeiraGTx Holdings plc: Chief Medical Officer Acquires 90,000 Restricted Share Units

Robert K. Zeldin, Chief Medical Officer of MeiraGTx Holdings plc, reports the acquisition of 90,000 restricted share units on April 3, 2025.

Summary

• Robert K. Zeldin, the Chief Medical Officer of MeiraGTx Holdings plc, filed a Form 4 on April 7, 2025, reporting a transaction.
• On April 3, 2025, Zeldin acquired 90,000 restricted share units (RSUs).
• These RSUs convert into ordinary shares on a 1:1 basis upon vesting.
• The vesting schedule is as follows: 50% on the second anniversary of the grant date, and 25% on each of the third and fourth anniversaries.
• Following the transaction, Zeldin directly owns 90,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating equity compensation, which is neither overtly positive nor negative.

Positives

• The acquisition of restricted share units by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the restricted share units extends over several years, suggesting a long-term commitment from the executive.

Industry Context

This type of equity compensation is common in the biotech industry to align executive incentives with shareholder value.

Comparison to Industry Standards

• Equity compensation is a standard practice across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen often use restricted stock units as part of their executive compensation packages.
• The vesting schedule described is fairly typical, aligning with industry norms for retaining key personnel.

Stakeholder Impact

• Shareholders may view this as a positive sign of executive alignment with company goals.
• Employees may see this as a standard part of the company's compensation practices.

Key Dates

Keywords

Restricted Share Units, Form 4, MGTX, MeiraGTx Holdings, Zeldin, Beneficial Ownership, Officer